Près d’un homme sur deux opéré d’un cancer de la prostate à haut risque voit la maladie revenir. Un nouveau schéma avec ...

Compared to conventional imaging techniques, prostate specific membrane antigen (PSMA) PET imaging provides superior ...

The addition of apalutamide to androgen deprivation therapy before and after surgery improved outcomes among men with ...

A previous trial involving patients with metastatic prostate cancer that was resistant to androgen pathway modulation (formerly referred to as castration-resistant) showed that adding talazoparib ...

A Phase III clinical trial led by Neeraj Agarwal, MD, FASCO, senior director of clinical research at Huntsman Cancer Institute and professor of internal medicine at the University of Utah (the U), has ...

Despite a lack of level 1 evidence, metastasis-directed therapy has been increasingly used for the treatment of oligometastatic prostate cancer based on findings from several randomized phase II ...

SAN FRANCISCO -- Progression-free survival (PFS) in oligometastatic prostate cancer improved significantly with metastasis-directed therapy (MDT) in addition to systemic treatment, a meta-analysis of ...

PSMA-PET has an important role in the accurate staging of recurrent prostate cancer. Prostate-specific membrane antigen-positron emission tomography (PSMA-PET) frequently detects metastatic disease ...

L'Erleada, le médicament contre le cancer de la prostate de Johnson & Johnson, administré en complément d'une hormonothérapie six mois avant et après une intervention chirurgicale, a amélioré les ...

A new study led by researchers at the UCLA Health Jonsson Comprehensive Cancer Center has found that many cases of high-risk nonmetastatic hormone-sensitive prostate cancer may be more advanced than ...

The largest real-world study ever conducted on prostate cancer in Brazil analyzed data from 670,205 patients treated through ...

Les résultats de l’essai international PROTEUS, présentés à l’ASCO en mai 2026, marquent un tournant majeur dans le ...